Comparison of efficacy and safety among axitinib, sunitinib, and sorafenib as neoadjuvant therapy for renal cell carcinoma: a retrospective study

Comparison of efficacy and safety among axitinib, sunitinib, and sorafenib as neoadjuvant therapy for renal cell carcinoma: a retrospective study

Bibliographic Details
Main Authors:	Wen Cai, Biao Cai, Juan Zhou, Yonghui Chen, Jin Zhang, Yiran Huang, Wei Xue, Jiwei Huang
Format:	Article
Language:	English
Published:	Wiley 2019-10-01
Series:	Cancer Communications
Online Access:	http://link.springer.com/article/10.1186/s40880-019-0405-5

Similar Items

Comparison of efficacy, safety, and quality of life between sorafenib and sunitinib as first-line therapy for Chinese patients with metastatic renal cell carcinoma
by: Wen Cai, et al.
Published: (2017-08-01)

Drug-Induced Hypertension Caused by Multikinase Inhibitors (Sorafenib, Sunitinib, Lenvatinib and Axitinib) in Renal Cell Carcinoma Treatment
by: Nanna Bæk Møller, et al.
Published: (2019-09-01)

Comparative efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: a systematic review and meta-analysis
by: Wang H, et al.
Published: (2016-06-01)

Evaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinoma
by: Gunnarsson O, et al.
Published: (2015-02-01)

A Cost-Effectiveness Analysis: First-Line Avelumab Plus Axitinib Versus Sunitinib for Advanced Renal-Cell Carcinoma
by: Peiyao Lu, et al.
Published: (2020-05-01)

Case report of a renal cell carcinoma patient with acute pancreatitis under both sunitinib and axitinib treatment
by: Utku Oflazoglu, et al.
Published: (2016-08-01)

Low-dose axitinib rechallenge with positive outcomes in a patient with metastatic renal cell carcinoma refractory to interferon α, sunitinib, axitinib, and nivolumab therapies: a case report
by: Masaki Murata, et al.
Published: (2019-04-01)

Outcomes of axitinib versus sunitinib as first‐line therapy to patients with metastatic renal cell carcinoma in the immune‐oncology era
by: Kazuyuki Numakura, et al.
Published: (2021-09-01)

Axitinib: A Review of its Safety and Efficacy in the Treatment of Adults with Advanced Renal Cell Carcinoma
by: Marine Gross-Goupil, et al.
Published: (2013-01-01)

Axitinib: A Review of its Safety and Efficacy in the Treatment of Adults with Advanced Renal Cell Carcinoma
by: Marine Gross-Goupil, et al.
Published: (2013-10-01)

THE SIDE EFFECTS OF SORAFENIB, SUNITINIB, AND TEMSIROLIMUS AND THEIR THERAPY IN PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA
by: N. Bhojani, et al.
Published: (2014-08-01)

THE SIDE EFFECTS OF SORAFENIB, SUNITINIB, AND TEMSIROLIMUS AND THEIR THERAPY IN PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA
by: N. Bhojani, et al.
Published: (2014-08-01)

Effects and Side Effects of Using Sorafenib and Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma
by: Caroline Randrup Hansen, et al.
Published: (2017-02-01)

Comparative Efficacy, Safety, and Costs of Sorafenib vs. Sunitinib as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
by: Huan Deng, et al.
Published: (2019-06-01)

Second-line treatment with axitinib plus toripalimab in metastatic renal cell carcinoma: a retrospective multicenter study
by: Huang, J., et al.
Published: (2022)

Axitinib after Sunitinib in metastatic renal cancer: preliminary results from Italian “Real-Word” SAX study
by: Carmine D'Aniello, et al.
Published: (2016-09-01)

Sorafenib neoadjuvant therapy in the treatment of high risk renal cell carcinoma.
by: Yushi Zhang, et al.
Published: (2015-01-01)

Sorafenib and sunitinib: A dermatologist′s perspective
by: Vijendran Pragasam, et al.
Published: (2014-01-01)

Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses
by: Irina Proskorovsky, et al.
Published: (2018-12-01)

Axitinib, cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated renal cell carcinoma: a systematic review and economic evaluation
by: Steve J Edwards, et al.
Published: (2018-01-01)

Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation
by: J Thompson Coon, et al.
Published: (2010-01-01)

Haemoglobin level increase as an efficacy biomarker during axitinib treatment for metastatic renal cell carcinoma: a retrospective study
by: Alison C. Johnson, et al.
Published: (2017-05-01)

Sunitinib efficacy in patients with disseminated renal cell carcinoma
by: O. B. Karyakin, et al.
Published: (2020-02-01)

Axitinib in sequential therapy in metastatic renal cell carcinoma
by: Agata Kuchar, et al.
Published: (2015-05-01)

Postoperative Adjuvant Sorafenib or Sunitinib for Nonmetastatic Renal Cell Carcinoma with Venous Tumor Thrombus: a Prospective Cohort Study
by: Liangyou Gu, et al.
Published: (2017-12-01)

Axitinib versus sorafenib as a second-line therapy in Asian patients with metastatic renal cell carcinoma: results from a randomized registrational study
by: Qin S, et al.
Published: (2015-06-01)

Efficacy and safety of cytokines versus first-line sunitinib and second-line axitinib for patients with metastatic renal cell carcinoma (ESCAPE study): A study protocol for phase III randomized sequential open-label study
by: Yoshifumi Kadono, et al.
Published: (2019-09-01)

Sites of disease as predictors of outcome in metastatic renal cell carcinoma patients treated with first-line sunitinib or sorafenib
by: Paolo Grassi, et al.
Published: (2015-04-01)

Efficacy and Safety of Individualized Schedule of Sunitinib by Drug Monitoring in Patients with Metastatic Renal Cell Carcinoma
by: Zhu X, et al.
Published: (2021-08-01)

Safety and efficacy of sorafenib in the treatment of hepatocellular carcinoma
by: Khaldoun Almhanna, et al.
Published: (2009-11-01)

Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma
by: Ansari J, et al.
Published: (2013-02-01)

Targeted treatments in advanced renal cell carcinoma: focus on axitinib
by: Verzoni E, et al.
Published: (2014-03-01)

Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives
by: Narayan V, et al.
Published: (2016-03-01)

Axitinib in metastatic renal cell carcinoma: single center experience
by: Agnieszka Buraczewska, et al.
Published: (2017-01-01)

Sphingosine kinase 1 overexpression contributes to sunitinib resistance in clear cell renal cell carcinoma
by: Yunze Xu, et al.
Published: (2018-12-01)

Heme oxygenase-1 is a predictive biomarker for therapeutic targeting of advanced clear cell renal cell carcinoma treated with sorafenib or sunitinib
by: Zheng WX, et al.
Published: (2015-08-01)

Efficacy and Safety of Sorafenib Therapy on Metastatic Renal Cell Carcinoma in Korean Patients: Results from a Retrospective Multicenter Study.
by: Sung Han Kim, et al.
Published: (2015-01-01)

Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib
by: Chris Coppin
Published: (2010-04-01)

Initial Experience of Sorafenib Neoadjuvant Therapy Combined with Retroperitoneoscopy in Treating T2 Large Renal Carcinoma
by: Chun-hua Lin, et al.
Published: (2015-01-01)

Neoadjuvant Sorafenib Treatment of Clear Cell Renal Cell Carcinoma and Release of Circulating Tumor Fragments
by: Gursah Kats-Ugurlu, et al.
Published: (2014-03-01)